Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Ovarian Neoplasms × Saline Solution × Clear all

Phase

Phase 3 3 Phase 4 2 Phase NA 1 Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Thrombocythemia, Essential 1 Sezary Syndrome 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Polycythemia Vera 1 Pdgfra-Associated Chronic Eosinophilic Leukemia 1 Pain, Postoperative 1 Ovarian Neoplasms 1 Neuralgia 1 Neoplasms, Plasma Cell 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Mycosis Fungoides 1 Multiple Myeloma 1 Lymphoproliferative Disorders 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, Extranodal NK-T-Cell 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Leukemia, Prolymphocytic 1

Interventions

Carboplatin 44 Paclitaxel 27 pembrolizumab 23 Cyclophosphamide 18 Nivolumab 14 Bevacizumab 13 Topotecan 12 liposomal doxorubicin 10 Filgrastim 10 Cisplatin 10 olaparib 9 Peripheral Blood Stem Cell Transplantation 9 Gemcitabine 9 fludarabine 8 durvalumab 7 aldesleukin 6 Ipilimumab 6 Interleukin-2 6 niraparib 5 epacadostat 5 Ifosfamide 5 Docetaxel 5 poly ICLC 4 pazopanib 4 cemiplimab 4 atezolizumab 4 Temozolomide 4 Specimen Handling 4 Oxaliplatin 4 Fulvestrant 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06888921 2026-02-27

MAIA-ovarian

Compugen Ltd

Phase 1/2 Recruiting

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡